Esperion (ESPR) General Counsel Benjamin Looker Sells 1,689 Shares

What Happened

• Benjamin Looker, General Counsel of Esperion Therapeutics (ESPR), sold 1,689 shares on January 20, 2026 at $2.88 per share for proceeds of $4,868. The filing indicates the sale was an open market or private sale and the shares were disposed to satisfy a tax obligation on vested restricted stock units (RSUs).

Key Details

• Transaction date and price: 2026-01-20, 1,689 shares at $2.88 each.
• Total proceeds: $4,868.
• Reason/footnote: Sale made to satisfy tax withholding on vested RSUs (footnote F1).
• Filing date: 2026-01-21; filing appears timely (no late filing indicated).
• Shares owned after transaction: Not specified in the provided summary of the filing.

Context

• This was a sale to cover tax obligations related to vested RSUs, a common and routine reason for insider sales (tax withholding), and not necessarily a signal of negative views on the company. No options were exercised and no 10b5-1 plan or other special trading arrangement was reported in the provided details.